Trafermin (Nobelpharma)

N/A

Report date: 2024/11/20 09:57:31

Base Information

Drug NameTrafermin (Nobelpharma)
Drug Alias NameNPC-18
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionAngiogenesis inducersFibroblast growth factor receptors agonists
TargetsFibroblast growth factor receptors
Therapy Area/IndicationsTympanic Membrane Perforation
Global Approved IndicationsTympanic Membrane Perforation
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2019/09/20
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesTranslational Research Informatics CenterNobelpharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Nuberen Pharmaceutical Co Ltd
Inactive CompaniesNobelpharma Co Ltd
Active IndicationsTympanic Membrane Perforation
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A